DECIPHERA PHARMACEUTICALS IN's ticker is DCPH and the CUSIP is 24344T101. A total of 157 filers reported holding DECIPHERA PHARMACEUTICALS IN in Q3 2023. The put-call ratio across all filers is 0.02 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,188 | +397.1% | 93,410 | +503.0% | 0.06% | +409.1% |
| Q1 2023 | $239 | +3.5% | 15,492 | +10.1% | 0.01% | -15.4% |
| Q4 2022 | $231 | -100.0% | 14,076 | -56.8% | 0.01% | -63.9% |
| Q3 2022 | $603,000 | +40.6% | 32,606 | +0.0% | 0.04% | +12.5% |
| Q2 2022 | $429,000 | +163.2% | 32,591 | +85.4% | 0.03% | +190.9% |
| Q1 2022 | $163,000 | +49.5% | 17,581 | +56.9% | 0.01% | -21.4% |
| Q4 2021 | $109,000 | -71.4% | 11,203 | 0.0% | 0.01% | -72.5% |
| Q3 2021 | $381,000 | +57.4% | 11,203 | +163.9% | 0.05% | -26.1% |
| Q4 2020 | $242,000 | +11.0% | 4,245 | 0.0% | 0.07% | 0.0% |
| Q3 2020 | $218,000 | -45.5% | 4,245 | -36.6% | 0.07% | -49.3% |
| Q2 2020 | $400,000 | +22.0% | 6,693 | -15.9% | 0.14% | -1.4% |
| Q1 2020 | $328,000 | -3.0% | 7,956 | -20.2% | 0.14% | +9.5% |
| Q3 2019 | $338,000 | – | 9,965 | – | 0.13% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| New Leaf Venture Partners, L.L.C. | 4,104,140 | $93,041,000 | 43.52% |
| SV Health Investors, LLC | 1,716,303 | $38,909,000 | 20.55% |
| PURA VIDA INVESTMENTS, LLC | 68,154 | $1,545,000 | 0.65% |
| Redmile Group, LLC | 683,880 | $14,658,000 | 0.64% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 77,000 | $1,746,000 | 0.62% |
| SPHERA FUNDS MANAGEMENT LTD. | 224,154 | $5,008,000 | 0.59% |
| EMERALD ADVISERS, LLC | 482,626 | $10,941,000 | 0.42% |
| EMERALD MUTUAL FUND ADVISERS TRUST | 416,342 | $9,438,000 | 0.38% |
| Orbimed Advisors | 1,176,070 | $26,662,000 | 0.34% |
| VIKING GLOBAL INVESTORS LP | 2,394,625 | $54,286,000 | 0.33% |